Development of peptide vaccines in dengue

摘要: Dengue is one of the most important arboviral infections worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine available, it not efficacious against serotypes that infect living in South East Asia, where an endemic disease. Hence, there urgent need develop efficient for this region. Data from different clinical trials indicate successful must elicit both neutralizing antibodies cell mediated immunity. This can be achieved by designing multi-epitope peptide comprising B, CD8+ CD4+ T epitopes. As recognition epitopes are restricted human leukocyte antigens (HLA), which able recognize several major HLAs will preferentially included design. While vaccines safe, biocompatible cost-effective, poorly immunogenic. Strategies improve its immunogenicity use long peptides, adjuvants nanoparticle delivery mechanisms discussed.